Phase
Condition
Lymphoma, B-cell
Lymphoma
Chronic Lymphocytic Leukemia
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥ 18 years
- Patient with CLL or indolent B-NHL who received the first COVID-19 prophylaxis dosewith Tixagevimab and Cilgavimab as per label indication between March 2022 and October
- Signed informed consent, if applicable
Exclusion
Exclusion Criteria: None
Study Design
Study Description
Connect with a study center
UOC Ematologia AO Cosenza
Cosenza,
ItalyActive - Recruiting
Ematologia AOU S.Anna
Ferrara,
ItalyActive - Recruiting
Ematologia AOU Careggi
Firenze,
ItalyActive - Recruiting
ASST Lecco Ospedale A.Manzoni
Lecco,
ItalyActive - Recruiting
UOC Ematologia ATMO
Livorno,
ItalyActive - Recruiting
ASST Grande Ospedale Metropolitano Niguarda
Milano,
ItalyActive - Recruiting
SCDU Ematologia
Novara,
ItalyActive - Recruiting
Dipartimento Oncologico La Maddalena
Palermo,
ItalyActive - Recruiting
UOC DI ONCOEMATOLOGIA AOR Villa Sofia - Cervello
Palermo,
ItalyActive - Recruiting
Ematologia Università "Sapienza" Roma
Roma,
ItalyActive - Recruiting
IRCCS Istituto Clinico Humanitas
Rozzano,
ItalyActive - Recruiting
UOC Ematologia Casa Sollievo della Sofferenza
San Giovanni Rotondo,
ItalyActive - Recruiting
SCDU Ematologia e terapie cellulari AO Mauriziano
Torino,
ItalyActive - Recruiting
Ematologia Ospedale S.Chiara
Trento,
ItalyActive - Recruiting
UOC ematologia ULSS2 Marca Trevigiana
Treviso,
ItalyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.